Tag: MONOGRAPH

  • Hydrafinil

    Plain-language summaryIntrigue 42 / 100

    Hydrafinil (9-fluorenol) is a wakefulness-promoting compound chemically distinct from the modafinil family. Cephalon explored it in early-stage research as a possible alternative scaffold for eugeroic activity. Limited clinical data are available. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Fluorenol-class eugeroic agent with weak dopamine reuptake inhibition and putative 5-HT6 receptor antagonism

    A tricyclic fluorenol alcohol investigated by Cephalon as a next-generation wakefulness-promoting agent, distinguished from the diphenylmethylsulfinyl modafinil scaffold by higher eugeroic potency in rodent assays, weaker dopamine transporter affinity, proposed 5-HT6 receptor antagonism, and the absence of human clinical development.

    Abstract

    Hydrafinil (9H-fluoren-9-ol; 9-fluorenol; CAS 1689-64-1; molecular formula C13H10O; molecular weight 182.22 g/mol) is a secondary benzylic alcohol of the fluorene ring system that emerged from a Cephalon Pharmaceuticals drug discovery program seeking structural successors to the eugeroic modafinil. In the three-part structure-activity relationship series published by Dunn, Hostetler, Iqbal, and colleagues in Bioorganic and Medicinal Chemistry Letters in 2012, fluorenol was identified as the most efficacious wakefulness-promoting compound among more than twenty candidates evaluated in rat locomotor and electroencephalographic sleep-wake assays, producing approximately 39 percent greater wakefulness than equimolar modafinil over a four-hour observation window [1, 2, 3]. This eugeroic superiority was observed despite a substantially weaker affinity for the dopamine transporter (DAT), with a reported IC50 of approximately 9 micromolar for dopamine reuptake inhibition compared to 3.7 micromolar for modafinil [4]. The dissociation between DAT affinity and eugeroic potency suggested the involvement of non-dopaminergic mechanisms; subsequent pharmacological characterization has identified 5-HT6 serotonin receptor antagonism as a plausible contributor to the wakefulness and procognitive profile, and a free radical-mediated mechanism involving dissociative electron transfer has been proposed on the basis of computational and spectroscopic evidence [5, 6].

    Cephalon elected not to advance fluorenol into clinical development, instead directing resources toward armodafinil (the R-enantiomer of modafinil), which received United States Food and Drug Administration approval in 2007. The compound has therefore never undergone Phase 1 pharmacokinetic characterization, formal toxicology evaluation, or human clinical trials. It entered the research chemical market in the early 2010s under the trade name “hydrafinil” and has since been widely available from nootropic and chemical vendors at purities of 98 percent or greater, typically as the crystalline solid.

    The pharmacokinetic profile is inferred from physicochemical properties, the Knoop et al. (2021) single-dose urinary metabolite study in three healthy volunteers, and structural analogy to related fluorene derivatives. Fluorenol is lipophilic (LogP approximately 2.4, higher than modafinil at 1.7), suggesting favorable blood-brain barrier penetration. Urinary metabolites identified by Knoop et al. include hydroxylated fluorenol conjugated as glucuronides and sulfates, indicating Phase I aromatic hydroxylation followed by Phase II conjugation as the principal elimination pathway [7]. The compound showed no affinity for cytochrome P450 2C19 in preliminary screening, distinguishing it from modafinil, which is a moderate CYP2C19 inhibitor. Formal plasma half-life, bioavailability, volume of distribution, and clearance parameters have not been determined in controlled pharmacokinetic studies.

    The safety profile of hydrafinil is largely uncharacterized. No LD50 values have been established in standard toxicology models. The compound is not listed as a carcinogen by ACGIH, IARC, NTP, or California Proposition 65. Material safety data sheets note potential for skin irritation and gastrointestinal irritation on ingestion. No long-term toxicology, reproductive toxicology, or genotoxicity studies have been published. The World Anti-Doping Agency (WADA) classified hydrafinil as a non-specified stimulant under category S6.A of the 2025 Prohibited List, effective January 1, 2025 [8]. The compound is not scheduled under the United States Controlled Substances Act, is not approved by the FDA or any other regulatory agency for any indication, and is sold exclusively as a research chemical. Investigators should treat hydrafinil as an experimental compound with a sparse evidence base and should not extrapolate clinical expectations from the preclinical eugeroic data without substantial additional characterization.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1440Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Sunifiram

    Plain-language summaryIntrigue 55 / 100

    Sunifiram is a small molecule developed in Italy as a cognitive enhancer. It positively modulates AMPA glutamate receptors and produces nootropic effects in animal studies at very low doses (sub-milligram range). Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Piperazine-derived nootropic with glycine-site NMDA receptor facilitation and indirect AMPA receptor-dependent cognition enhancement

    A piperazine-derived cognition enhancer synthesized at the University of Florence as a molecular simplification of unifiram, distinguished from the racetam class by four-orders-of-magnitude greater antiamnesic potency in rodent models and a mechanism operating through the glycine-binding site of the NMDA receptor with downstream CaMKII and PKC-alpha activation, though lacking any human clinical data or formal toxicology record.

    Abstract

    Sunifiram (DM-235; 1-benzoyl-4-propanoylpiperazine; CAS 314728-85-3; molecular formula C14H18N2O2; molecular weight 246.31 g/mol) is a synthetic piperazine-derived nootropic compound first disclosed at the University of Florence in approximately 2000 by the Gualtieri research group as a molecular simplification of unifiram (DM-232), itself a bicyclic diazabicyclononanone derivative of the racetam pharmacophore. Despite frequent categorization in the research-chemical literature as an ampakine or racetam analogue, sunifiram is structurally distinct from both classes: it lacks the pyrrolidone ring system that defines the racetam family and does not directly potentiate AMPA receptor currents in the manner of canonical ampakines such as CX-516 or aniracetam. The compound was identified through a program of systematic structural simplification of the piracetam scaffold, in which opening of the pyrrolidone ring and substitution with an acyl piperazine yielded a series of agents with substantially enhanced antiamnesic potency in the mouse passive avoidance test. Sunifiram prevents scopolamine-induced amnesia in mice at intraperitoneal doses of 0.001 to 0.1 mg/kg and at oral doses of 0.01 to 0.1 mg/kg, placing its molar potency approximately four orders of magnitude greater than piracetam and comparable on a per-weight basis to the most potent nootropic agents in the preclinical literature. The compound additionally reverses amnesia induced by mecamylamine (a nicotinic antagonist), baclofen (a GABA-B agonist), and clonidine (an alpha-2 adrenergic agonist), indicating broad-spectrum antiamnesic activity across multiple neurotransmission systems rather than a single-receptor mechanism. In vitro, sunifiram does not display measurable affinity for any of the major central nervous system receptor classes (glutamate, GABA, serotonin, dopamine, adrenergic, histamine, acetylcholine, or opioid) at concentrations up to 10 micromolar in standard radioligand displacement assays. However, the compound enhances long-term potentiation in mouse hippocampal CA1 slices at nanomolar concentrations (10 to 100 nM) with a bell-shaped dose-response relationship, an effect blocked by 7-chlorokynurenic acid (a glycine-site NMDA receptor antagonist) but not by ifenprodil (a polyamine-site NMDA receptor antagonist). This pharmacological dissection, reported by Bhatt et al. (2013), established the glycine-binding site of the NMDA receptor as the principal locus of sunifiram action, with downstream activation of calcium/calmodulin-dependent protein kinase II (CaMKII) and protein kinase C-alpha (PKC-alpha) mediating the synaptic potentiation and the behavioral antiamnesic effect. In the olfactory bulbectomized (OBX) mouse model of cognitive deficit and depression, Moriguchi et al. (2013) demonstrated that oral sunifiram at 0.01 to 1.0 mg/kg daily for 7 to 12 days significantly improved spatial reference memory (Y-maze) and short-term recognition memory (novel object recognition) and restored hippocampal long-term potentiation, without ameliorating depressive behaviors in the tail suspension test. The dissociation between cognitive and affective endpoints supports a mechanism localized to glutamatergic synaptic plasticity rather than monoaminergic mood regulation. Sunifiram increases the release of acetylcholine from rat cerebral cortex in vitro, an effect shared with unifiram and potentially contributing to the procognitive profile. The compound does not impair motor coordination on the rotarod test, does not modify spontaneous locomotor activity on the Animex apparatus, and does not alter inspection activity on the hole board test at effective antiamnesic doses, indicating a clean behavioral profile at therapeutic-range concentrations. As of the most recent monograph revision, sunifiram has not been subjected to formal toxicology testing in any species, has not entered human clinical trials in any jurisdiction, is not approved for medical use anywhere in the world, and is classified by the United States Food and Drug Administration as an unapproved new drug with unlawful use in dietary supplements, food, or medicine. The compound is sold as a research chemical by multiple vendors at purities typically exceeding 98 percent by HPLC. Research-grade vendor literature suggests human doses of 5 to 10 mg per administration, scaled from rodent allometric conversion, but this dose range has not been validated by human pharmacokinetic or safety data. This monograph reviews the chemistry, synthesis, and structure-activity relationships of sunifiram; the glycine-site NMDA receptor mechanism in molecular and electrophysiological detail; the preclinical pharmacology across multiple amnesia models; the absent pharmacokinetic and clinical record; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five nootropic cognition enhancers against sunifiram on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1435Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • DMAE

    Plain-language summaryIntrigue 38 / 100

    DMAE (2-(dimethylamino)ethanol) is a small molecule structurally related to choline that crosses the blood-brain barrier easily. The hypothesis has long been that it acts as a precursor to acetylcholine and phosphatidylcholine in the brain, but the evidence has been mixed and DMAE may actually be more of a methyl donor than a true cholinergic precursor. Its predecessor, deanol, was sold for ADHD until pulled from the US market in the 1980s for inadequate efficacy data. It survives in nootropic supplements and in topical skin-firming creams (the cosmetic mechanism is poorly understood). Reports of headaches and worsened depression in some users. Long-running compound with weak underlying evidence. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Tertiary aminoalcohol choline analog and putative acetylcholine precursor with antioxidant and membrane-active properties

    A naturally occurring dimethylated ethanolamine historically developed as the prescription drug Deaner for pediatric behavioral disorders, subsequently investigated for tardive dyskinesia, senile dementia, and dermatological aging, and now positioned as a dietary supplement cholinergic agent distinguished from conventional choline sources by competitive blood-brain barrier transport affinity and membrane phospholipid incorporation.

    Abstract

    Dimethylaminoethanol (DMAE), also known as deanol or 2-(dimethylamino)ethanol, is a tertiary aminoalcohol endogenous to human brain tissue and present at nutritionally relevant concentrations in certain marine fish species (sardines, anchovies, salmon). Structurally, DMAE differs from choline (2-hydroxyethyltrimethylammonium) by the absence of one N-methyl group, a distinction that confers higher lipophilicity, competitive affinity for the choline carrier at the blood-brain barrier (inhibition constant approximately 159 micromolar versus Michaelis constant approximately 442 micromolar for choline), and the capacity for incorporation into membrane phospholipids as phosphatidyldimethylaminoethanol (PDMAE) in place of phosphatidylcholine. The compound was developed by Riker Laboratories as deanol p-acetamidobenzoate (Deaner) and marketed from the 1960s through 1983 as a prescription medication for hyperkinetic syndrome (now termed attention-deficit/hyperactivity disorder) in children, on the basis of placebo-controlled trials demonstrating behavioral improvement comparable to methylphenidate at oral doses of 300 to 500 mg per day. The drug was voluntarily withdrawn in 1983 when the manufacturer elected not to submit the contemporary efficacy data required by evolving FDA regulatory standards, rather than for safety concerns. Subsequent clinical investigation extended to tardive dyskinesia, senile dementia, and dermatological applications. In tardive dyskinesia, a Cochrane systematic review and meta-analysis of randomized controlled trials concluded that DMAE was no more effective than placebo and was associated with an increased risk of adverse outcomes [1]. In senile dementia, open-label and small controlled trials produced modest behavioral improvements without measurable cognitive or memory enhancement [2]. The dermatological evidence base is more favorable: a randomized, double-blind, placebo-controlled trial of 3 percent DMAE facial gel applied daily for 16 weeks demonstrated statistically significant improvements in forehead lines, periorbital fine wrinkles, lip shape, and overall facial skin appearance, with effects maintained on cessation and safety confirmed through 12 months of open-label extension [3]. The pharmacological mechanism remains incompletely resolved. The classical hypothesis that DMAE serves as a direct acetylcholine precursor through sequential methylation to choline and subsequent acetylation by choline acetyltransferase has been challenged by disposition studies demonstrating that DMAE is not metabolized to choline in vivo and that its principal urinary metabolite is DMAE N-oxide [4]. Alternative mechanistic proposals include competitive inhibition of choline reuptake at the blood-brain barrier (thereby elevating peripheral choline concentrations), direct incorporation into neuronal membrane phospholipids as PDMAE with consequent alteration of membrane fluidity and receptor function, free radical scavenging activity against hydroxyl and lipid radicals confirmed by electron paramagnetic resonance spectroscopy [5], and anti-inflammatory activity through suppression of interleukin-2 and interleukin-6 secretion. DMAE is also the active moiety released by hydrolysis of centrophenoxine (meclofenoxate), a nootropic drug marketed in several jurisdictions for age-related cognitive decline, in which the para-chlorophenoxyacetic acid ester linkage enhances oral bioavailability and central nervous system penetration. The compound is currently available worldwide as a dietary supplement, typically formulated as the bitartrate salt at doses of 100 to 400 mg per day. The National Toxicology Program conducted prenatal developmental toxicity studies of DMAE bitartrate in Sprague Dawley rats (2020) and reported no maternal or fetal toxicity at gavage doses up to 1000 mg/kg/day, although in vitro exposure of neurulating mouse embryos to DMAE produced dose-dependent neural tube defects and craniofacial malformations at concentrations of 250 to 750 micromolar [6]. This monograph reviews the chemistry, structural relationships, and synthesis of DMAE; the contested cholinergic pharmacology in molecular and membrane-level detail; the comprehensive disposition and pharmacokinetic record; the preclinical evidence base spanning free radical scavenging, anti-inflammatory activity, and lipofuscin reduction; the clinical evidence across behavioral, neurological, cognitive, and dermatological indications; sourcing and quality verification considerations for research-grade material; reconstitution and handling protocols; stack interactions with choline donors, acetylcholinesterase inhibitors, and anticholinergic agents; adverse events and safety signals including the NTP developmental toxicity findings; and a structured comparative assessment of five cholinergic and nootropic alternatives against DMAE on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1447Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Flmodafinil

    Plain-language summaryIntrigue 48 / 100

    Flmodafinil is a fluorinated version of modafinil developed at the same Lafon laboratory in the 1980s. It reportedly binds the dopamine transporter more tightly than modafinil with longer duration. It never advanced to clinical development. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Bisfluorinated diphenylmethyl sulfinyl acetamide eugeroic and selective atypical dopamine reuptake inhibitor

    A bis(4-fluorophenyl) ring-substituted analog of modafinil developed at Laboratoire L. Lafon, distinguished from the parent compound by enhanced dopamine transporter affinity, prolonged wake-promoting duration, absence of cytochrome P450 enzyme induction, and a preclinical pharmacology profile suggesting superior potency-to-dose ratio with reduced sleep architecture disruption.

    Abstract

    Flmodafinil (CRL-40,940; NLS-4; lauflumide; bisfluoromodafinil; JBG01-41) is a synthetic eugeroic of the diphenylmethyl sulfinyl acetamide structural class, bearing two para-fluorine substituents on the phenyl rings of the modafinil scaffold. First synthesized and patented by Laboratoire L. Lafon in France in the mid-1980s as part of a systematic structure-activity exploration of modafinil derivatives, the compound remained largely uninvestigated for approximately two decades until NLS Pharmaceutics AG (formerly NLS Pharmaceuticals) acquired development rights and advanced it into preclinical programs for narcolepsy, attention deficit hyperactivity disorder, Alzheimer’s disease, idiopathic hypersomnia, and chronic fatigue syndrome. The compound acts as a selective atypical dopamine reuptake inhibitor with a binding affinity (Ki) of 4,090 nM at the dopamine transporter, approximately 12-fold selectivity over the serotonin transporter (Ki 48,700 nM), and negligible affinity for the sigma-1 receptor (Ki greater than 100,000 nM). In functional assays, flmodafinil blocks the dopamine transporter by approximately 83 percent, exceeding the inhibition produced by methylphenidate without concurrent adrenergic effects. Both the (S)-(+) enantiomer (JBG1-048, Ki 2,970 nM) and the (R)-(-) enantiomer (JBG1-049, Ki 4,830 nM) elevate extracellular dopamine in the rat nucleus accumbens to 150 to 200 percent of baseline at the highest assessed doses, with the (R)-(-) enantiomer producing a notably slower onset and longer duration of dopaminergic effect compared to (R)-modafinil. In the principal comparative preclinical study (Luca et al. 2018), NLS-4 at 64 mg/kg intraperitoneally in C57BL/6J mice induced approximately 151 minutes of additional wakefulness compared to approximately 110 minutes for modafinil at 150 mg/kg, a 2.3-fold higher dose, establishing that flmodafinil possesses substantially greater wake-promoting potency per milligram than the parent compound. Recovery sleep following NLS-4-induced wakefulness was characterized by less non-rapid eye movement (NREM) sleep amount and attenuated delta power elevation compared to modafinil-treated animals, suggesting a qualitatively different and possibly more favorable recovery profile with reduced homeostatic sleep pressure accumulation despite longer drug-induced wakefulness. A subsequent preclinical study in a rat model of chronic severe fatigue (Konofal et al. 2023) reported that NLS-4 at 16 mg/kg produced locomotor activity restoration comparable to modafinil at 64 mg/kg, confirming a four-fold potency advantage with more sustained effects on circadian activity patterns. Unlike modafinil, flmodafinil does not induce cytochrome P450 CYP3A4 or CYP3A5 enzymes in human hepatocyte cultures, a pharmacologically significant distinction that reduces the potential for drug-drug interactions in chronic dosing regimens. The compound has not been approved for medical use in any jurisdiction. Clinical development programs initiated by NLS Pharmaceutics for narcolepsy, ADHD, and Alzheimer’s disease have been discontinued without publication of human trial data; preclinical development for chronic fatigue syndrome remains the only active program as of the most recent public disclosure. No published human clinical trial data exist for flmodafinil. The World Anti-Doping Agency has initiated investigations into urinary metabolism and detection methods for flmodafinil and its structural relative fladrafinil (CRL-40,941), confirming regulatory awareness of the compound in the context of competitive sport. This monograph reviews the chemistry, synthesis, and stereochemistry of flmodafinil; the dopamine transporter pharmacology and enantiomer-resolved binding data; the preclinical wake-promoting and chronic fatigue evidence; the pharmacokinetic profile as characterized in animal models; sourcing and quality verification considerations for laboratory work; and a comparative assessment of five eugeroic and wakefulness-promoting alternatives against flmodafinil on five competency standards. The compound is supplied exclusively as a research-grade preparation; investigators should obtain analytical confirmation of identity, purity, and enantiomeric composition on every lot.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1438Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Unifiram

    Plain-language summaryIntrigue 38 / 100

    Unifiram is closely related to sunifiram with similar AMPA receptor modulation. Both are research compounds with limited clinical evaluation. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Piperazine-derived ampakine-like nootropic with AMPA receptor-mediated cognition-enhancing activity

    A hexahydropyrrolo[1,2-a]pyrazinone cognition enhancer synthesized at the University of Florence, approximately 1000-fold more potent than piracetam in rodent antiamnesic assays, operating through AMPA receptor-dependent glutamatergic facilitation and cholinergic release enhancement without direct binding to any characterized central receptor.

    Abstract

    Unifiram (DM-232) is an experimental nootropic compound of the hexahydropyrrolo[1,2-a]pyrazinone structural class, synthesized in the late 1990s at the University of Florence by the research group led by Fulvio Gualtieri within the Department of Pharmaceutical Sciences. The compound was first disclosed in 2000 and characterized in a series of publications by Ghelardini, Galeotti, Romanelli, and colleagues between 2002 and 2006. Unifiram is approximately 1000-fold more potent than piracetam in the mouse passive avoidance test and the rat Morris water maze, the standard behavioral assays for antiamnesic and procognitive activity in the racetam research tradition. The compound prevents amnesia induced by scopolamine (muscarinic antagonism), mecamylamine (nicotinic antagonism), baclofen (GABA-B agonism), and clonidine (alpha-2 adrenergic agonism) at intraperitoneal doses of 0.001 to 0.1 mg/kg and oral doses of 0.01 to 0.1 mg/kg in mice, with no impairment of motor coordination on the rota rod test at doses up to 10 mg/kg.

    The mechanism of action is not fully elucidated, but the available evidence supports AMPA receptor-dependent glutamatergic facilitation as the principal pharmacological activity. Unifiram reverses amnesia induced by the selective AMPA receptor antagonist NBQX, increases the amplitude of field excitatory postsynaptic potentials (fEPSP) in rat hippocampal slices in a concentration-dependent manner, and stimulates acetylcholine release from rat cerebral cortex in vitro. Despite these functional effects, unifiram shows no measurable affinity for any of the principal central nervous system receptors, ion channels, or transporters at concentrations up to 1 micromolar in standard radioligand binding panels, including glutamate (AMPA, NMDA, kainate), GABA, serotonin, dopamine, adrenergic, histamine, muscarinic, nicotinic, and opioid sites. The compound therefore appears to operate through an indirect or allosteric mechanism on AMPA receptor-mediated neurotransmission rather than through direct orthosteric binding.

    Sunifiram (DM-235), the molecular simplification of unifiram produced by the same research group, retains comparable potency and shares the AMPA-dependent mechanism. A third analog, sapunifiram (MN-19), has also been characterized with similar activity. The structure-activity relationship program at Florence explored modifications of the piperazine and bicyclic ring systems and identified compounds with amnesing (pro-amnestic) activity of comparable potency to scopolamine, confirming the pharmacological specificity of the cognition-enhancing scaffold.

    No human clinical trials of unifiram have been conducted. No formal toxicology studies beyond acute rodent dosing have been published. The compound was never patented, and by approximately 2012 it appeared on commercial websites as a consumer nootropic despite the absence of human safety or efficacy data. The 2015 commentary by Gualtieri in the Journal of Enzyme Inhibition and Medicinal Chemistry characterized the commercial availability of unifiram and sunifiram as an illustration of academic and industrial shortcomings in the translation of early-stage research compounds. The compound is not approved for human use in any jurisdiction. It is not scheduled as a controlled substance in most jurisdictions but is sold as a research chemical. Investigators should obtain analytical confirmation of identity and purity on every lot and should not extrapolate rodent dose-response data to human applications without appropriate pharmacokinetic and safety characterization.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1434Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Centrophenoxine

    Plain-language summaryIntrigue 52 / 100

    Centrophenoxine (meclofenoxate) is a 1959-vintage cognitive enhancer that pairs DMAE, a choline-related compound, with a small chlorinated acid. After it crosses into the brain, it splits and does two things: it feeds the acetylcholine system and it helps clear lipofuscin, the brownish junk pigment that accumulates inside aged brain and skin cells. The lipofuscin clearance angle is the unusual part; few compounds do it. It has been sold as a memory drug in Europe and Latin America since the 1960s for senile cognitive impairment, but the modern clinical evidence is thin and mostly old. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Cholinergic precursor ester combining dimethylaminoethanol and 4-chlorophenoxyacetic acid with lipofuscin-clearing and neuroprotective activity

    A synthetic ester of dimethylaminoethanol and para-chlorophenoxyacetic acid developed in 1959 at the French National Scientific Research Center, distinguished from other cholinergic precursors by its capacity to reduce neuronal lipofuscin accumulation and to enhance phospholipid membrane turnover in aging brain tissue.

    Abstract

    Centrophenoxine (meclofenoxate, Lucidril; 2-(dimethylamino)ethyl (4-chlorophenoxy)acetate; CAS 51-68-3; molecular formula C12H16ClNO3; molecular weight 257.71 g/mol) is a synthetic cholinergic precursor and neuroprotective agent developed in 1959 at the Centre National de la Recherche Scientifique (CNRS) in France. The compound is an ester of two biologically active moieties: dimethylaminoethanol (DMAE), a naturally occurring aminoalcohol found in small quantities in the human brain and implicated in choline and phospholipid metabolism, and para-chlorophenoxyacetic acid (pCPA), a synthetic auxin derivative that serves as a lipophilic carrier facilitating blood-brain barrier penetration and extending the biological half-life of the DMAE component. Following oral administration, centrophenoxine undergoes rapid hepatic ester hydrolysis to release DMAE and pCPA. The DMAE moiety is subsequently methylated to choline, which enters the acetylcholine synthetic pathway and is incorporated into membrane phospholipids as phosphatidyldimethylaminoethanol and phosphatidylcholine. The compound’s most distinctive pharmacological feature is the reduction of lipofuscin, the heterogeneous age pigment that accumulates progressively in postmitotic cells including cortical and hippocampal neurons, cardiac myocytes, and retinal pigment epithelium. The lipofuscin-clearing activity was first demonstrated by Nandy and Bourne in 1966 in senile guinea pig neurons and has been replicated across multiple rodent species, with reductions of 25 to 40 percent in cortical and hippocampal lipofuscin content following chronic oral administration at doses of 40 to 80 mg/kg/day for three to six months [1, 2]. The mechanism of lipofuscin clearance is incompletely characterized but is attributed to a combination of enhanced lysosomal enzyme activity, increased membrane phospholipid turnover (which dilutes the lipofuscin granule burden through membrane remodeling), and direct free radical scavenging by the DMAE moiety, which is incorporated into neuronal membranes as phosphatidyl-DMAE and functions as a hydroxyl radical scavenger [3, 4]. The clinical evidence base in human cognitive impairment spans approximately five decades but is modest in scale and quality by contemporary standards. The largest double-blind, randomized, placebo-controlled trial in healthy elderly subjects (Marcer and Hopkins, 1977; n = 50) demonstrated significant improvement in delayed free recall after three months of oral centrophenoxine at 600 mg twice daily, with no effect on immediate recall, digit span, or recognition memory, suggesting a selective enhancement of memory consolidation into long-term storage [5]. A second double-blind trial in 50 patients with organic dementia (Pek and Fulop, 1983) reported improvement in 48 percent of centrophenoxine-treated subjects versus 28 percent on placebo, although with high variability and methodological limitations [6]. Smaller open-label and controlled studies have reported improvements in vigilance, reaction time, and subjective mental alertness in elderly populations. The compound is marketed as a prescription medicine in several European countries (France, Germany, Hungary, Austria), in Japan, and in parts of Latin America for indications including senile cognitive impairment, post-stroke cognitive rehabilitation, and alcohol-related cognitive decline. It is not approved by the United States Food and Drug Administration and is sold as a research chemical in the United States. Pharmacokinetics are characterized by rapid oral absorption, rapid hepatic ester hydrolysis (plasma half-life of the parent ester is approximately 30 to 60 minutes), and a longer effective duration attributable to the persistence of the DMAE metabolite in brain tissue. Typical clinical doses range from 600 to 2000 mg per day in two or three divided administrations. The adverse-event profile is favorable; the most commonly reported effects are mild gastrointestinal discomfort, insomnia, and headache, generally at higher doses and resolving with dose reduction. This monograph reviews the chemistry, synthesis, and structural pharmacology of centrophenoxine; the lipofuscin-clearing, cholinergic, antioxidant, and membrane-modifying mechanisms; the pharmacokinetic profile; the preclinical and clinical evidence base; sourcing and quality verification; reconstitution and handling; stack interactions with racetams and other cholinergic agents; the adverse-event and safety profile; and a comparative assessment of five cholinergic and neuroprotective alternatives (alpha-GPC, citicoline, DMAE, piracetam, and idebenone) against centrophenoxine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1445Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Fladrafinil

    Plain-language summaryIntrigue 38 / 100

    Fladrafinil is the fluorinated cousin of adrafinil from the same Lafon series. It is a prodrug that the liver converts to flmodafinil. Sparse pharmacology data suggest similar profile to flmodafinil with slightly shorter onset. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Fluorinated diphenylmethylsulfinyl hydroxamic acid eugeroic and prodrug of flmodafinil

    A bis(4-fluorophenyl)-substituted analog of adrafinil developed at Laboratoire L. Lafon as a wakefulness-promoting agent with reported anti-aggressive properties in animal models, functioning as a prodrug of the dopamine transporter inhibitor flmodafinil and distinguished from its parent compound by fluorine substitution at both para-phenyl positions.

    Abstract

    Fladrafinil (CRL-40,941), also designated fluorafinil and bisfluoroadrafinil, is a synthetic diphenylmethylsulfinyl hydroxamic acid eugeroic compound first synthesized at Laboratoire L. Lafon in Paris in the late 1970s to early 1980s as part of the benzhydryl sulfinyl series that also produced adrafinil (CRL-40,028) and modafinil (CRL-40,476). The compound is the bis(4-fluoro) ring-substituted derivative of adrafinil and functions as a prodrug that undergoes hepatic amide hydrolysis to yield flmodafinil (CRL-40,940, bisfluoromodafinil), a selective atypical dopamine reuptake inhibitor with a reported dopamine transporter (DAT) Ki of approximately 4,090 nM and 83 percent DAT blockade in vitro [1, 2]. Fladrafinil was disclosed in a 1984 United States patent (US 4,489,095) assigned to Lafon, in which preclinical animal data demonstrated wakefulness promotion and, distinctively, anti-aggressive behavioral effects in rodent aggression paradigms at intraperitoneal doses of 16 to 1,024 mg/kg, a property not shared by the parent compound adrafinil [3]. The anti-aggressive activity, reported at potencies three to four times greater than adrafinil on a weight basis, represented the principal pharmacological distinction identified during the original Lafon screening campaign and suggested a differentiated central nervous system profile relative to the non-fluorinated congeners. Despite these early findings, fladrafinil was never advanced to formal clinical development. No peer-reviewed human pharmacokinetic, efficacy, or safety studies have been published. The compound was not registered in any jurisdiction and was not assigned an International Nonproprietary Name. The pharmacological characterization of fladrafinil therefore rests entirely on the Lafon patent disclosures, on inference from the well-characterized pharmacology of its active metabolite flmodafinil and of the closely related modafinil and adrafinil, and on recent analytical chemistry investigations conducted under the auspices of the World Anti-Doping Agency (WADA) to establish urinary and blood detection markers for anti-doping surveillance [4, 5]. Flmodafinil itself has been characterized as a selective DAT inhibitor that blocks the dopamine transporter at 83 percent occupancy without inducing cytochrome P450 3A4 or 3A5, that maintains wakefulness over a longer timeframe than modafinil in animal models with reduced perturbation of sleep architecture, and that elevates nucleus accumbens dopamine concentrations by approximately 150 to 200 percent at peak doses [1, 2]. The active metabolite has been in preclinical development for chronic fatigue syndrome, though clinical programs for narcolepsy, attention deficit hyperactivity disorder, and Alzheimer’s disease have been discontinued as of early 2024. Fladrafinil entered public awareness principally through the nootropic and dietary supplement markets beginning approximately 2015, where it is sold as a research-grade powder or capsule preparation at purities typically stated as 98 percent or greater. The compound is classified under the WADA Prohibited List as a class S6 non-specified stimulant (prohibited in-competition) and has been the subject of analytical investigations by Krug, Thevis, and colleagues at the German Sport University Cologne into its metabolism, elimination kinetics, and detection windows in urine and dried blood spots [4, 5]. This monograph reviews the chemistry, structural relationships, known and inferred pharmacology, pharmacokinetics, the absence of clinical evidence, sourcing and quality considerations, reconstitution and handling, stack interactions, adverse-event signal, and a comparative assessment of five eugeroic and wakefulness-promoting compounds against fladrafinil on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1439Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • IDRA-21

    Plain-language summaryIntrigue 50 / 100

    IDRA-21 is a benzothiadiazide ampakine developed at the University of Milan. It enhances AMPA receptor function and showed cognitive enhancement in primate studies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Benzothiadiazine-class positive allosteric modulator of AMPA-type glutamate receptors (ampakine)

    A benzothiadiazine derivative developed at the Nathan S. Kline Institute as a partial negative allosteric modulator of AMPA receptor desensitization, distinguished from cyclothiazide and the racetam-class ampakines by partial intrinsic activity, prolonged duration of cognitive enhancement, absence of neurotoxicity at pharmacologically active doses, and oral bioavailability with central nervous system penetration in rodent and primate species.

    Abstract

    IDRA-21 (7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide; CAS 22503-72-6; molecular formula C8H9ClN2O2S; molecular weight 232.69 g/mol) is a benzothiadiazine derivative that acts as a positive allosteric modulator of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type glutamate receptors by attenuating receptor desensitization. The compound was synthesized and characterized at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York, under the direction of Erminio Costa and Alessandro Guidotti in the early 1990s, and was advanced through preclinical development by Fidia Farmaceutici SpA of Abano Terme, Italy, before discontinuation in October 2003 without entry into human clinical trials.

    The mechanism of action is partial negative allosteric modulation of AMPA receptor desensitization, a pharmacological property that distinguishes IDRA-21 from the full modulators cyclothiazide and diazoxide. In cultured cerebellar granule neurons, IDRA-21 increases the sodium transient with a threshold concentration approximately 10-fold higher than cyclothiazide and an intrinsic activity significantly lower than that of cyclothiazide, producing a shorter-lasting calcium transient and, critically, complete absence of neurotoxicity at concentrations up to 100 micromolar in the presence of AMPA, compared to the severe neurotoxicity produced by cyclothiazide at 5 to 25 micromolar under identical conditions. The partial modulator mechanism therefore provides a wide therapeutic index between the concentrations that enhance cognition and those that produce excitotoxic neuronal injury.

    The compound is a chiral molecule possessing one stereocenter at the 3-position of the benzothiadiazine ring. Enantiomeric resolution by Uzunov et al. (1995) using a custom chiral stationary phase demonstrated that the dextrorotatory (+)-IDRA-21 enantiomer is the pharmacologically active form in rat water maze performance, whereas the levorotatory (-)-enantiomer is devoid of activity at comparable doses. The racemate has been used in all published in vivo behavioral studies.

    Preclinical cognitive enhancement has been documented across multiple species, behavioral paradigms, and impairment models. In rat passive avoidance and water maze tasks, racemic IDRA-21 at oral doses of 1 to 3 micromol/kg reverses cognitive deficits induced by alprazolam (a GABAergic positive modulator) and scopolamine (a muscarinic antagonist), with effect persisting for 3 to 4 hours after a single oral dose. In patas monkeys working in a complex operant learning task, IDRA-21 at 3 to 5.6 mg/kg orally antagonized alprazolam-induced learning deficits and was estimated to be approximately 10-fold more potent than aniracetam in this paradigm. In young adult and aged rhesus monkeys performing a delayed matching-to-sample task, oral IDRA-21 at 0.15 to 10 mg/kg produced robust improvements in task accuracy, with effects sustained to 48 hours after a single dose and accuracy on long-delay (most difficult) trials increased by up to 34 percent of vehicle at the individualized best dose. In young macaques performing a visual recognition memory task, oral IDRA-21 significantly improved performance on the longest delay condition.

    A secondary pharmacological activity has been characterized: IDRA-21 negatively modulates NMDA receptor function in cultured cerebellar granule cells, with partial selectivity for NR2B-containing receptor assemblies. The NMDA receptor inhibition is neither competitive nor voltage-dependent and may contribute to the neuroprotective and cognitive profiles by tempering excessive NMDA receptor activation while potentiating AMPA receptor currents.

    The principal safety concern identified in preclinical studies is the enhancement of ischemic neuronal injury. Yamada et al. (1998) demonstrated that IDRA-21 at 12 and 24 mg/kg orally increases CA1 hippocampal neuron loss following 10 minutes of global ischemia in rats, and that glutamate plus IDRA-21 produces AMPA receptor-dependent neurotoxicity in cultured hippocampal neurons. This finding has implications for any future clinical development in populations at risk of cerebrovascular events.

    No human clinical trials have been conducted with IDRA-21. The compound was discontinued from development by Fidia Farmaceutici in October 2003. It remains available from multiple research-grade chemical suppliers at greater than 98 percent purity and is used as a reference compound in AMPA receptor pharmacology research and as a tool compound for the study of glutamatergic contributions to cognition and synaptic plasticity.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1436Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Solriamfetol

    Plain-language summaryIntrigue 68 / 100

    Solriamfetol, sold as Sunosi, is a wakefulness-promoting medication FDA-approved in 2019 for daytime sleepiness in narcolepsy and obstructive sleep apnea. It is a selective dopamine and norepinephrine reuptake inhibitor with clean pharmacology. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Selective dopamine and norepinephrine reuptake inhibitor (DNRI) with trace amine-associated receptor 1 (TAAR1) agonist activity

    A phenylalanine-derived dual dopamine-norepinephrine reuptake inhibitor developed by SK Biopharmaceuticals and commercialized by Jazz Pharmaceuticals as the first DNRI approved for the treatment of excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea.

    Abstract

    Solriamfetol (JZP-110, SKL-N05, ADX-N05) is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) approved in the United States (March 2019) and the European Union (January 2020) for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy or obstructive sleep apnea (OSA). Chemically derived from the amino acid D-phenylalanine, solriamfetol is the (R)-enantiomer of 2-amino-3-phenylpropyl carbamate and is supplied as the hydrochloride salt for oral administration. The compound inhibits the reuptake of dopamine (IC50 approximately 2.9 micromolar) and norepinephrine (IC50 approximately 4.4 micromolar) at their respective plasma membrane transporters (DAT and NET) with minimal activity at the serotonin transporter. In addition, solriamfetol acts as an agonist at the human trace amine-associated receptor 1 (TAAR1) with an EC50 of approximately 10 to 16 micromolar, a concentration range overlapping its DAT and NET inhibitory potencies and achieved at clinically relevant plasma levels. Critically, the compound does not promote monoamine release, distinguishing it mechanistically from amphetamine and its analogs and supporting its classification as a reuptake inhibitor rather than a releasing agent. The clinical development program comprised five pivotal trials (TONES 1 through TONES 5). The Phase 3 TONES 2 trial in 231 narcolepsy patients demonstrated that solriamfetol at 150 mg and 300 mg once daily produced statistically significant improvements in the Maintenance of Wakefulness Test (MWT) mean sleep latency (increases of 9.8 and 12.3 minutes, respectively, versus 2.1 minutes for placebo at 12 weeks) and in the Epworth Sleepiness Scale (ESS). The Phase 3 TONES 3 trial in 459 OSA patients demonstrated similar dose-dependent improvements at 37.5, 75, 150, and 300 mg doses. The long-term TONES 5 open-label extension in 643 participants confirmed maintenance of efficacy and tolerability over 52 weeks. A randomized withdrawal phase within TONES 5 demonstrated that participants switched to placebo experienced a return of sleepiness (ESS worsening of 5.3 points versus 1.6 points for those continuing solriamfetol), confirming sustained pharmacological activity rather than natural remission. Pharmacokinetics are notable for high oral bioavailability (approximately 95 percent), minimal hepatic metabolism (less than 1 percent of dose recovered as the sole inactive metabolite N-acetyl solriamfetol), and predominant renal elimination of unchanged drug through active tubular secretion. The elimination half-life is approximately 7.1 hours in subjects with normal renal function. Because metabolism is negligible, solriamfetol carries essentially no cytochrome P450 drug interaction liability. However, renal impairment substantially prolongs elimination (half-life increased approximately 1.2-, 1.9-, and 3.9-fold in mild, moderate, and severe renal impairment, respectively), requiring dose adjustment in moderate and severe renal impairment and avoidance in end-stage renal disease. The principal adverse events are headache, nausea, decreased appetite, insomnia, and anxiety. Solriamfetol produces small, dose-dependent increases in systolic blood pressure (0.5 to 2.5 mmHg), diastolic blood pressure, and heart rate (0.7 to 2.9 beats per minute), consistent with its noradrenergic mechanism. Concurrent use with monoamine oxidase inhibitors is contraindicated. The compound is designated Schedule IV in the United States, reflecting low but measurable abuse potential at supratherapeutic doses. This monograph reviews the chemistry, synthesis, and stereochemistry of solriamfetol; the dual-transporter and TAAR1 pharmacology; the comprehensive pharmacokinetic profile; the clinical evidence base across narcolepsy and OSA indications; the sourcing and quality verification considerations for research applications; reconstitution and handling; stack-interaction implications; adverse-event signal; and a comparative assessment of five wake-promoting agents against solriamfetol on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1441Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • TB-500 Fragment

    Synthetic heptapeptide fragment of thymosin beta-4 encompassing the actin-binding domain (residues 17-23) with N-terminal acetylation

    A synthetic N-acetylated heptapeptide (Ac-LKKTETQ) derived from the central actin-binding domain of thymosin beta-4, investigated for tissue repair, angiogenesis, anti-inflammatory activity, and wound healing through modulation of actin polymerization dynamics and cellular migration.

    Abstract

    TB-500 Fragment (Ac-LKKTETQ) is a synthetic heptapeptide corresponding to residues 17 through 23 of the endogenous 43-amino acid polypeptide thymosin beta-4, a ubiquitous intracellular G-actin sequestering protein that participates in cytoskeletal organization, cell migration, angiogenesis, and tissue repair. The fragment encompasses the central actin-binding domain of the parent molecule and is N-terminally acetylated to confer resistance to aminopeptidase degradation and to replicate the post-translational modification present on native thymosin beta-4. TB-500 Fragment has been the subject of substantial preclinical investigation since the early 2000s, when Philp et al. (2003) demonstrated that the synthetic LKKTETQ heptapeptide promoted dermal wound repair in db/db diabetic mice and in aged mice at efficacy levels comparable to the full-length thymosin beta-4 molecule, establishing the actin-binding domain as a sufficient pharmacophore for the tissue repair activity of the parent protein. The principal molecular mechanism of TB-500 Fragment is sequestration of G-actin monomers and modulation of actin polymerization dynamics, which promotes cell migration, endothelial tube formation, keratinocyte mobilization, and extracellular matrix remodeling. Downstream signaling involves activation of integrin-linked kinase (ILK), phosphorylation of Akt/protein kinase B, suppression of NF-kappaB-mediated proinflammatory cytokine release, and upregulation of matrix metalloproteinases that facilitate tissue remodeling during wound repair. The pharmacological profile of TB-500 Fragment is therefore characterized by four principal activities: promotion of angiogenesis, acceleration of wound healing, anti-inflammatory modulation, and facilitation of stem and progenitor cell migration. Preclinical evidence in rodent models has demonstrated accelerated dermal wound closure in diabetic and aged animals, cardioprotection following experimental myocardial infarction (demonstrated with the parent thymosin beta-4 molecule in the landmark Bock-Marquette et al. 2004 Nature study), promotion of hair follicle stem cell activation and hair growth (Philp et al. 2004), and anti-inflammatory activity through suppression of NF-kappaB nuclear translocation and reduction of TNF-alpha and IL-1-beta production. Human clinical data for the heptapeptide fragment itself are limited; the majority of clinical evidence derives from the full-length thymosin beta-4 molecule, which has been evaluated in Phase 2 and Phase 3 clinical trials for dry eye disease (RGN-259, RegeneRx Biopharmaceuticals) and in Phase 2 studies for neurotrophic keratopathy. The Phase 2 dry eye trial demonstrated statistically significant improvements in ocular discomfort (35.1 percent reduction) and corneal fluorescein staining (59.1 percent reduction) relative to vehicle control. The Phase 3 ARISE program in dry eye disease did not meet co-primary endpoints, though statistically significant improvement in ocular grittiness was observed. TB-500 Fragment is not approved by any regulatory authority for human therapeutic use. It is classified as a prohibited substance by the World Anti-Doping Agency under Sections S0 (Non-Approved Substances) and S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) and is prohibited in equine racing competition by multiple national racing authorities. Pharmacokinetic data from preclinical studies indicate a plasma elimination half-life of approximately 1.5 to 3 hours following subcutaneous administration, with subcutaneous bioavailability of approximately 60 to 80 percent relative to intravenous dosing; tissue-level effects persist substantially longer than plasma residence, consistent with the intracellular mechanism of action. The compound is supplied as a lyophilized powder and is reconstituted in bacteriostatic water for injection; it is stable at refrigerated conditions for up to 30 days after reconstitution. This monograph reviews the chemistry, synthesis, and structural characterization of TB-500 Fragment; the molecular pharmacology of actin sequestration, ILK activation, and NF-kappaB suppression; the pharmacokinetic profile; the preclinical evidence base across wound healing, cardiac repair, hair growth, and anti-inflammatory models; the clinical evidence derived from the parent thymosin beta-4 molecule; sourcing and quality verification; reconstitution and handling; stack interaction considerations; adverse event and safety signal assessment; and a comparative evaluation of five alternative tissue repair and regenerative peptides against TB-500 Fragment on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1451Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.